Very Positive Press Coverage Unlikely to Affect Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price
Media stories about Ultragenyx Pharmaceutical (NASDAQ:RARE) have trended very positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ultragenyx Pharmaceutical earned a daily sentiment score of 0.60 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 33 out of 100, meaning that recent media coverage is unlikely to have an effect on the stock’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- What’s Behind Ultragenyx Pharmaceutical Inc (RARE)? Technical Indicators Under Review – FLBC News (flbcnews.com)
- Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : August 3, 2017 (finance.yahoo.com)
- Ultragenyx Pharmaceutical Inc (RARE) Shares Placed Under the Microscope – Financial News Review (finnewsreview.com)
- Ultragenyx Pharmaceutical Inc (RARE) MFI Reading Under the Microscope – Evergreen Caller (evergreencaller.com)
- Waters Corporation (WAT) is worth at $173.44, Ultragenyx Pharmaceutical Inc. (RARE) closed at $66.32 per share – Stocks Gallery (stocksgallery.com)
Ultragenyx Pharmaceutical (NASDAQ RARE) traded up 1.13% during mid-day trading on Friday, reaching $63.30. The company’s stock had a trading volume of 168,714 shares. Ultragenyx Pharmaceutical has a 12-month low of $51.67 and a 12-month high of $91.35. The stock’s market cap is $2.69 billion. The firm’s 50 day moving average price is $65.11 and its 200 day moving average price is $67.53.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.73) by $0.01. During the same period last year, the firm posted ($1.46) earnings per share. On average, equities analysts predict that Ultragenyx Pharmaceutical will post ($7.08) earnings per share for the current year.
RARE has been the subject of several analyst reports. SunTrust Banks, Inc. increased their target price on Ultragenyx Pharmaceutical from $100.00 to $105.00 and gave the company a “buy” rating in a research report on Wednesday, April 19th. Canaccord Genuity reiterated a “buy” rating and set a $100.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, April 19th. Stifel Nicolaus reiterated a “buy” rating and set a $111.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 30th. BidaskClub upgraded Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Tuesday, July 25th. Finally, Morgan Stanley lowered their price target on Ultragenyx Pharmaceutical from $84.00 to $79.00 and set an “equal weight” rating for the company in a research report on Monday, May 8th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and eight have assigned a buy rating to the stock. Ultragenyx Pharmaceutical presently has a consensus rating of “Hold” and a consensus price target of $84.67.
ILLEGAL ACTIVITY WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/04/very-favorable-press-coverage-unlikely-to-affect-ultragenyx-pharmaceutical-nasdaqrare-share-price-updated-updated-updated.html.
In related news, VP Theodore Alan Huizenga sold 480 shares of Ultragenyx Pharmaceutical stock in a transaction on Friday, May 26th. The stock was sold at an average price of $57.46, for a total value of $27,580.80. Following the transaction, the vice president now owns 9,366 shares in the company, valued at $538,170.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 9.20% of the stock is currently owned by company insiders.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.